Cytosin-Arabinosid
B-Cell Non-Hodgkin Lymphoma
Mwanasha Merrill, MDPhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 67/ 100
- Competitive Position
- 81/ 100
Competitive context
17 Active assets in the B-Cell Non-Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 4 | BB |
Anti-Thymoglobulin, Rabbit Stanford University | Phase 2 | B |
Acalabrutinib AstraZeneca | Phase 2 | B |
VINCRISTINE SULFATE David Bond, MD | Phase 2 | B |
Nivolumab National Cancer Institute (NCI) | Phase 2 | B |
View all 23 →
Same molecule, other indications
Cytosin-Arabinosid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →